NAP spans 42 months and proposes a novel science-to-technology paradigm to assess the ability of the next generation of biohybrid in vitro brains to serve as downscaled and personalized models of sleep, and to predict sleep-related early signs of Parkinsons' Disease.
NAP objectives
NAP breakthroughs
The first model enabling the study of individual sleep habits
The cyborganoid: the next generation of models of the human brain.
A new procedure mimicking personalized sleep
A new unified way to study sleep, from cells to humans
A new tool for predicting Parkinson's Disease.
NAP in a nutshell
NAP breakthroughs and specific objectives are achieved through:
the collaborative development (e.g., cyborganoid)
the application of common experimental approaches (e.g., scaling-based drug stimulation for in vitro functional/structural characterization, and the use of allometry for defining sleep in cells and humans)
the use of complementary technologies (e.g., electrophysiology and calcium imaging)
the comparison of observations across groups (from in vitro constructs up to humans, accounting sex).